phase 3 trials, page-2

Hi Eddy, I'm not sure it would make much difference. Data about to be released from the phase 2b trial will provide info on the long term efficacy. Number-wise, the phase 3 will involve about 20 times more people, so rolling in the phase 2 participants wouldn't make a lot of difference. I realise there is the potential for some further info by tracking the phase 2 people who stay on the drug, but it would be unlikely to make much difference in terms of the time to market, or people's perception of how the trial(s) are going.